TY - JOUR A2 - MAGI-Galluzzi，克里斯蒂娜AU - 叶，李福AU - 他，沙非盟 - 吴，培AU - 江圣英AU - 张，若陈AU - 杨，泽曲AU - 陈，法文AU - 潘，丹灵AU - 李，董AU - 李，刚PY - 2020 DA - 2020年1月31日TI - 前列腺检测癌抗原3和前列腺癌易感候选非-DRE尿提高诊断3964615 VL - - 2020 AB - 前列腺癌在中国人口SP的虽然前列腺活检是前列腺癌诊断的金标准，这也导致负活检的高发病率和临床低风险前列腺癌和随后的诊断过度治疗。它仍然是一个未被满足的需求，以推迟在临床实践中不必要的活检发现新的生物标志物。在这项研究中，我们描述了一种新方法，LBXexo得分，以测量来自非DRE尿尿液外来体PCA3 / PRAC表达作为一种非侵入性诊断，以改善与一低血清PSA水平在中国人群的检出率。第一空隙尿样品收集到分离外来体，并通过定量逆转录PCR测量PCA3和PRAC的外来体的RNA。在这两种任何级和高等级前列腺癌组中观察到在exoPCA3 / PRAC甲显著增加时与活检阴性组进行比较。接受者操作特性曲线分析表明，LBXexo得分显著改进的诊断性能预测活检结果，具有0.723的AUC（ p = 0.017 ）和0.736（ p = 0.038 ) for any-grade and high-grade (GS ≥ 7) prostate cancer, respectively. For high-grade cancer, LBXexo had the negative and positive predictive values of 100% and 27.59%, respectively, and could potentially avoid unnecessary biopsy. This is the first report in Chinese population that demonstrates the predictive value of the exosomal expression of PCA3 and PRAC derived from non-DRE urine in predicting prostate biopsy outcomes. It could be used in clinical practice to make a better informed biopsy decision and avoid unnecessary biopsies in Chinese population. SN - 2090-3111 UR - https://doi.org/10.1155/2020/3964615 DO - 10.1155/2020/3964615 JF - Prostate Cancer PB - Hindawi KW - ER -